Fujifilm to Buy Inspirata’s Digital Pathology Biz

Fujifilm Corp. has begun a deal to acquire Inspirata Inc.’s digital pathology business.
 
After the transaction is complete, Inspirata’s Dynamyx digital pathology tech, employees, and customers will become part of Fujifilm. Adding digital pathology will expand the company’s Synapse enterprise imaging offering to enable integrating pathology images and data into a healthcare organization’s electronic health record (EHR) system and streamline care delivery for oncology patients and providers.
 
This acquisition marks Fujifilm’s full-scale, global entry into the digital pathology market, where 85% of U.S., 86% of European, and 90% of Asian healthcare organizations are still running on analog.
 
“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” Teiichi Goto, president and CEO, representative director, Fujifilm told the press. “We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”
 
Dynamyx is an open, vendor-agnostic, end-to-end digital pathology tool. It can use whole slide images from multiple scanning vendors for an easier digitization experience, and pathology labs can benefit from faster results, centralized imaging records, and enterprise access to images for all clinicians. It’s installed in medical facilities that handle large volumes of pathological images across multiple lab locations, allowing use of their preferred mix of laboratory and diagnostic technologies with full compatibility.
 
It will become part of the company’s Synapse Enterprise Imaging suite of healthcare IT solutions that unify imaging, data access, and workflows across the health system. By adding digital pathology, Fujifilm will offer a comprehensive enterprise imaging portfolio consisting of VNA, Radiology PACS, and Cardiology PACS, as well as an enterprise information system, cloud services, and 3D advanced visualization. Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development.
 
“A $320 million global industry in 2021 projected to reach $640 million by 2025, the rising number of cancer cases and the demonstrated benefits of digital pathology are fueling significant demand and market growth in the hospital and pharmaceutical industries,” said Henry Izawa, president and CEO, FUJIFILM Healthcare Americas Corporation. “These evolving clinical needs fuel Fujifilm’s investment and innovation in the digital revolution, and we look forward to introducing Dynamyx and its host of unique features and benefits to our Synapse customers and prospects as we strive to enable more efficient medical diagnosis and high-quality care.”
 
“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the UK,” said Masa Fukumoto, managing director, FUJIFILM Healthcare Europe and senior vice president FUJIFILM Medical Systems Europe. “We’ve received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”